<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718679</url>
  </required_header>
  <id_info>
    <org_study_id>IVN-CAT-001B</org_study_id>
    <nct_id>NCT00718679</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial</brief_title>
  <acronym>IVN-CAT-001B</acronym>
  <official_title>Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImVision GmbH, Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is placebo controlled, double blind, randomised, two arm dose escalation of a new
      product for specific immunotherapy in cat allergic patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saftety tolerability and efficacy</measure>
    <time_frame>2009</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Allergy to Cat Dander</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVN201</intervention_name>
    <description>Intralymphativ injection of the study drug</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  History and subjective symptoms of cat dander allergy including cat specific allergic
             rhinitis

          -  Age 18 to 65 years

          -  Positive reaction to at least one concentration of cat dander allergen in skin prick
             test, intradermal provocation test and nasal provocation test

        Exclusion criteria:

          -  Chronic infectious disease

          -  Acute infections

          -  Episode of non-allergic rhinitis within the last 4 weeks

          -  Use of allergen known to predict anaphylactic reactions

          -  Treatment with any other investigational drug within 3 months before trial entry

          -  Vaccination within the last week

          -  Nasal surgery within the last 8 weeks

          -  Progressive fatal disease

          -  Drug or alcohol abuse within the last 5 years

          -  Cat ownership

          -  A history of significant cardiac insufficiency (NYHA stage III-IV)

          -  Coexisting severe disease, e.g. cardiovascular diseases

          -  Acute or history of obstructive respiratory insufficiency ( FEV1 &lt;70%)

          -  Hepatic insufficiency

          -  Relevant anaemia (as judged by investigator)

          -  Blood donation within the last 30 days or intended blood donation (during the study or
             30 days after participation)

          -  Pregnancy or breast feeding

          -  Sexually active woman of childbearing potential not actively practicing birth control
             by using a medically accepted device or therapy

          -  Lack of compliance or other sililar reason, that the investigator believes, precludes
             satisfactory participation in the study

          -  Systemic glucocorticoid therapy

          -  Allergic asthma and chronic medication with steroids at doses exceeding 200ug/day
             Treatment with ATII antagonists, B-blocker, ACE inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Senti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Research University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>February 10, 2010</last_update_submitted>
  <last_update_submitted_qc>February 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Thomas KÃ¼ndig</name_title>
    <organization>University Hospital Zurich</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

